opdualag concentrate for solution for infusion 240mg80mg
bristol-myers squibb (singapore) pte. ltd. - nivolumab; relatlimab - infusion, solution concentrate - nivolumab 240mg per vial; relatlimab 80mg per vial
opdivo intravenous infusion 100mg (オプジーボ点滴静注100mg)
ono pharmaceutical co., ltd. - nivolumab (genetical recombination) - injection
opdivo intravenous infusion 100mg (オプジーボ点滴静注100mg)
bristol-myers squibb - nivolumab (genetical recombination) - injection
opdivo intravenous infusion 120mg (オプジーボ点滴静注120mg)
bristol-myers squibb - nivolumab (genetical recombination) - injection
opdivo intravenous infusion 120mg (オプジーボ点滴静注120mg)
ono pharmaceutical co., ltd. - nivolumab (genetical recombination) - injection
opdivo intravenous infusion 20mg (オプジーボ点滴静注20mg)
bristol-myers squibb - nivolumab (genetical recombination) - injection
opdivo intravenous infusion 20mg (オプジーボ点滴静注20mg)
ono pharmaceutical co., ltd. - nivolumab (genetical recombination) - injection
opdivo intravenous infusion 240mg (オプジーボ点滴静注240mg)
ono pharmaceutical co., ltd. - nivolumab (genetical recombination) - injection
opdivo intravenous infusion 240mg (オプジーボ点滴静注240mg)
bristol-myers squibb - nivolumab (genetical recombination) - injection
yervoy ipilimumab (rch) 200mg in 40ml (5mg/ml) concentrate solution for iv infusion vial
bristol-myers squibb australia pty ltd - ipilimumab, quantity: 213 mg - injection, concentrated - excipient ingredients: trometamol hydrochloride; sodium chloride; mannitol; pentetic acid; polysorbate 80; sodium hydroxide; hydrochloric acid; water for injections - melanoma,yervoy, as monotherapy, is indicated for the treatment of patients with unresectable or metastatic melanoma.,yervoy, in combination with nivolumab, is indicated for the treatment of patients with unresectable or metastatic melanoma. the approval of this indication is based on a pre-specified comparison to ipilimumab monotherapy. all analyses comparing nivolumab monotherapy with the nivolumab/ipilimumab combination are descriptive.,renal cell carcinoma (rcc),yervoy, in combination with nivolumab, is indicated for the treatment of patients with intermediate/poor-risk, previously untreated advanced renal cell carcinoma.,non-small cell lung cancer (nsclc),yervoy, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy, is indicated for the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer (nsclc) with no egfr or alk genomic tumour aberrations.,malignant pleural mesothelioma (mpm),yervoy, in combination with nivolumab, is indicated for the first-line treatment of patients with unresectable malignant pleural mesothelioma.,oesophageal squamous cell carcinoma (oscc),yervoy in combination with nivolumab is indicated for the first-line treatment of patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression greater than or equal to 1% as determined by a validated test.